^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kevetrin (thioureidobutyronitrile)

    i
    Other names: KM-3174
    Company:
    Innovation Pharma
    Drug class:
    p53 stimulant
    Related drugs:
    over4years
    [VIRTUAL] Development of TP53 targeted treatment strategy in esophageal squamous cell carcinoma based on clinical information, TP53 mutation status and p53 RNA expression level (AACR-II 2020)
    Drugs which have different effects were used, e.g. Fluorouracil, Cisplatin, APR-246 (which reactivates mutant p53), kevetrin (which activates wild p53). The function of ESCC is thought to differ depending on TP53 mutation status, and it is suggested that prognosis may be improved by the selection of drugs according to TP53 mutation status. We integrate and analyze clinical information and TP53 DNA, RNA status from ESCC specimens, and report this theme along with the relevant literature.
    Clinical
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 expression
    |
    cisplatin • eprenetapopt (APR-246) • Kevetrin (thioureidobutyronitrile)